Partnership to Promote Future Development of Multiplex Biomarker Testing

Under the terms of the agreement, Myriad RBM, Inc. (Austin, TX, USA) grants exclusive distribution rights, for research purposes, to Bio-Rad Laboratories, Inc. (Hercules, CA, USA). These rights apply to the large catalog of quantitative multiplexed immunoassays currently available to run on Bio-Rad's Bio-Plex 200, Bio-Plex 3D, and Bio-Plex MAGPIX instruments.

The assay kits acquired from Myriad RBM will expand the potential of Bio-Rad's instruments in the field of very low volume multiplex testing for research in toxicology, oncology, immunology, and cardiovascular and other diseases.

"Together we are able to provide hundreds of new biomarkers for both human and non-human panels to our Bio-Plex multiplex immunoassay system menu," said Brad Crutchfield, vice president and group manager of the life science group at Bio-Rad. "Moving forward, Myriad RBM and Bio-Rad will collaborate to design new products to meet the evolving requirements of our customers."

"This agreement combines Myriad RBM's industry-leading menu of multiplexed immunoassays with Bio-Rad’s unrivaled global commercial distribution capabilities," said Craig Benson, president of Myriad RBM. "Our partnership with Bio-Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care."

Related Links:
Myriad RBM, Inc.
Bio-Rad Laboratories, Inc.